Mutant BRAFT1799A can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 12, 2009, Pages 5001-5009

  Cradic, Kendall W ^a   Milosevic, Dragana ^a   Rosenberg, Anne M ^b   Erickson, Lori A ^a   McIver, Bryan ^a   Grebe, Stefan K G ^a  

^a MAYO CLINIC   (United States)

^b UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; THYROGLOBULIN;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER STAGING; CHILD; CROSS REACTION; DIPLOIDY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; ONCOCYTOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SCHOOL CHILD; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; WILD TYPE;

EID: 73249132998     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1349     Document Type: Article

References (32)

1. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627
2. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY 2004 Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 45:818-821
3. V599E mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 89:2414-2420
4. Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW, Sidransky D 2004 BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 89:1365-1368
5. Powell N, Jeremiah S, Morishita M, Dudley E, Bethel J, Bogdanova T, Tronko M, Thomas G 2005 Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. J Pathol 205:558-564
6. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK 2006 The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol 65:364-368
7. Goutas N, Vlachodimitropoulos D, Bouka M, Lazaris AC, Nasioulas G, Gazouli M 2008 BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res 28:305-308
8. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A 2007 The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246:466-470
9. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762
10. Nikiforova MN, Nikiforov YE 2008 Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 8:83-95
11. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE, Fagin JA 2005 Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65:4238-4245
12. Xing M, Tufano RP, Tufaro AP, Basaria S, Ewertz M, Rosenbaum E, Byrne PJ, Wang J, Sidransky D, Ladenson PW 2004 Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 89:2867-2872
13. Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, Sidransky D, Westra WH 2004 Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 10:2761-2765
14. Domingues R, Mendonca E, Sobrinho L, Bugalho MJ 2005 Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma. Cytopathology 16:27-31
15. Jin L, Sebo TJ, Nakamura N, Qian X, Oliveira A, Majerus JA, Johnson MR, Lloyd RV 2006 BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 15:136-143
16. Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park do J, Lee HS, Cho BY, Lee ES, Kim SW 2006 Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cytopathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol 65:660-666
17. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN 2009 Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 94:2092-2098
18. - targeting to the membrane. Endocr Rel Cancer 13:257-269
19. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379
20. Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, Elashoff D, Hoon DS 2006 Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg 244:799-804
21. Mojica WD, Khoury T 2006 Presence of the BRAF V600E point mutation in morphologically benign appearing thyroid inclusions of cervical lymph nodes. Endocr Pathol 17:183-189
22. Daniotti M, Vallacchi V, Rivoltini L, Patuzzo R, Santinami M, Arienti F, Cutolo G, Pierotti MA, Parmiani G, Rodolfo M 2007 Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer 120:2439-2444
23. Shinozaki M, O'Day SJ, Kitago M, Amersi F, Kuo C, Kim J, Wang HJ, Hoon DS 2007 Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res 13:2068-2074
24. Yancovitz M, Yoon J, Mikhail M, Gai W, Shapiro RL, Berman RS, Pavlick AC, Chapman PB, Osman I, Polsky D 2007 Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diagn 9:178-183
25. Vdovichenko KK, Markova SI, Belokhvostov AS 2004 Mutant form of BRAF gene in blood plasma of cancer patients. Ann NY Acad Sci 1022:228-231
26. Grebe SKG 2009 Diagnosis and management of thyroid carcinoma: a focus on serum thyroglobulin. Expert Rev Endocrinol Metab 4:25-43
27. Farrand K, Jovanovic L, Delahunt B, McIver B, Hay ID, Eberhardt NL, Grebe SKG 2002 Loss of heterozygosity studies revisited: prior quantification of amplifiable DNA content of archival samples improves efficiency and reliability. J Mol Diagn 4:150-158
28. Jovanovic L, Delahunt B, McIver B, Eberhardt NL, Grebe SKG 2008 Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. J Pathol 215:145-154
29. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA, Goellner JR 2002 Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26:870-885
30. Rowe LR, Bentz BG, Bentz JS 2007 Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis. J Clin Pathol 60:1211-1215
31. Fleischhacker M, Schmidt B 2007 Circulating nucleic acids (CNAs) and cancer: a survey. Biochim Biophys Acta 1775:181-232
32. Vasko V, Hu S, Wu G, Xing JC, Larin A, Savchenko V, Trink B, Xing M 2005 High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 90:5265-5269